BR112015026685A2 - agente de diminuição de ácido úrico - Google Patents

agente de diminuição de ácido úrico

Info

Publication number
BR112015026685A2
BR112015026685A2 BR112015026685A BR112015026685A BR112015026685A2 BR 112015026685 A2 BR112015026685 A2 BR 112015026685A2 BR 112015026685 A BR112015026685 A BR 112015026685A BR 112015026685 A BR112015026685 A BR 112015026685A BR 112015026685 A2 BR112015026685 A2 BR 112015026685A2
Authority
BR
Brazil
Prior art keywords
tyrosine
uric acid
lowering agent
acid lowering
cyclothyrosyl
Prior art date
Application number
BR112015026685A
Other languages
English (en)
Inventor
Watanabe Hiroshi
Fukizawa Shinya
Suzuki Toshihide
Beppu Yoshinori
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of BR112015026685A2 publication Critical patent/BR112015026685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)

Abstract

resumo patente de invenção: "agente de diminuição de ácido úrico". trata-se de um agente de diminuição de ácido úrico que contém, como um ingrediente ativo, um dipeptídeo cíclico contendo tirosina selecionado a partir de um grupo que consiste em ciclotriptofaniltirosina, cicloseriltirosina, cicloproliltirosina, ciclotirosilglicina, ciclotirosiltirosina, ciclofenilalaniltirosina, cicloleuciltirosina, ciclolisiltirosina, ciclohistidiltirosina, cicloalaniltirosina, cicloglutamiltirosina, ciclovaliltirosina, cicloisoleuciltirosina, ciclotreoniltirosina, cicloaspartiltirosina, cicloasparaginiltirosina, cicloglutaminiltirosina, cicloarginiltirosina, ciclometioniltirosina e ciclotirosilcisteína ou um sal dos mesmos. o agente de diminuição de ácido úrico da presente invenção tem uma excelente ação de diminuição de um nível de ácido úrico, e o agente de diminuição de ácido úrico é útil, por exemplo, na prevenção ou no tratamento de hiperuricemia, gota ou similar. 1/1
BR112015026685A 2014-06-20 2014-06-20 agente de diminuição de ácido úrico BR112015026685A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/066424 WO2015194034A1 (ja) 2014-06-20 2014-06-20 尿酸値低下剤

Publications (1)

Publication Number Publication Date
BR112015026685A2 true BR112015026685A2 (pt) 2017-07-25

Family

ID=52823346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026685A BR112015026685A2 (pt) 2014-06-20 2014-06-20 agente de diminuição de ácido úrico

Country Status (13)

Country Link
US (1) US9650415B2 (pt)
EP (1) EP3159005A1 (pt)
JP (1) JP5690028B1 (pt)
KR (1) KR20160022292A (pt)
CN (1) CN105407907A (pt)
AU (1) AU2014386720B2 (pt)
BR (1) BR112015026685A2 (pt)
CA (1) CA2904493A1 (pt)
HK (1) HK1215797A1 (pt)
MX (1) MX2015015162A (pt)
SG (1) SG11201507823RA (pt)
TW (1) TWI564018B (pt)
WO (1) WO2015194034A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6669497B2 (ja) 2013-06-10 2020-03-18 サントリーホールディングス株式会社 ジケトピペラジンを含有する植物エキス及びその製造方法
JP6713991B2 (ja) * 2015-07-02 2020-06-24 サントリーホールディングス株式会社 アルコール吸収抑制用組成物
WO2017002786A1 (ja) * 2015-07-02 2017-01-05 サントリーホールディングス株式会社 Ｇｌｐ－２分泌促進用組成物
JP6669750B2 (ja) * 2015-07-16 2020-03-18 サントリーホールディングス株式会社 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物
JP6666912B2 (ja) * 2015-07-17 2020-03-18 サントリーホールディングス株式会社 Ｔｒｐｖ１刺激用組成物
JP6777632B2 (ja) * 2015-07-27 2020-10-28 サントリーホールディングス株式会社 環状ジペプチド及び甘味料を含有する組成物
WO2017038799A1 (ja) * 2015-09-04 2017-03-09 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
KR20230047198A (ko) 2016-05-26 2023-04-06 가부시키가이샤 아미노 압 수면 개선제
JP2019011303A (ja) * 2017-07-03 2019-01-24 サントリーホールディングス株式会社 環状ジペプチドの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
ES2381775T3 (es) * 2000-08-04 2012-05-31 Dmi Biosciences, Inc. Procedimiento del uso de dicetopiperazinas y composición que las contiene
US7214673B2 (en) 2002-03-28 2007-05-08 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
AU2004241101B2 (en) * 2003-05-15 2010-05-13 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
JP2006111541A (ja) * 2004-10-12 2006-04-27 Toyo Shinyaku:Kk 葛花処理物を含有する経口用肌質改善剤
EP2088143A1 (en) * 2008-01-24 2009-08-12 Commissariat A L'energie Atomique Novel inhibitors of mycobacterium tuberculosis complex cytochrome P450 CYP121
CN102665717B (zh) 2009-12-25 2014-10-29 三得利控股株式会社 学习积极性改善剂
JP2013053115A (ja) * 2011-09-06 2013-03-21 Josho Gakuen α環状ジペプチドの製造方法
JP6669497B2 (ja) * 2013-06-10 2020-03-18 サントリーホールディングス株式会社 ジケトピペラジンを含有する植物エキス及びその製造方法

Also Published As

Publication number Publication date
AU2014386720A1 (en) 2016-01-21
TW201600103A (zh) 2016-01-01
CN105407907A (zh) 2016-03-16
US9650415B2 (en) 2017-05-16
US20160159858A1 (en) 2016-06-09
AU2014386720B2 (en) 2016-07-21
KR20160022292A (ko) 2016-02-29
SG11201507823RA (en) 2016-01-28
WO2015194034A1 (ja) 2015-12-23
HK1215797A1 (zh) 2016-09-15
MX2015015162A (es) 2016-03-15
JP5690028B1 (ja) 2015-03-25
TWI564018B (zh) 2017-01-01
EP3159005A1 (en) 2017-04-26
JPWO2015194034A1 (ja) 2017-04-20
CA2904493A1 (en) 2015-12-20

Similar Documents

Publication Publication Date Title
BR112015026685A2 (pt) agente de diminuição de ácido úrico
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
WO2017066121A9 (en) Controlled and precise treatment of cardiac tissues
BR112017003186A2 (pt) composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
EA201791467A1 (ru) Водный офтальмологический раствор
BR112019011769A2 (pt) composição de anticorpo anti-c5 aquosa estável
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
TW201625535A (en) Inhibitors of histone demethylases
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
AU2015275507A8 (en) Cyclic dipeptide-containing composition
BR112017004925A2 (pt) composição e método
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112017006425B8 (pt) Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]